PharmiWeb Recruiter Blog

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, now presents itself with a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners, and employees.

• New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19 pandemic, to accelerate epidemic and pandemic vaccine development
• First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness

CAMBRIDGE, MA / ACCESSWIRE / October 30, 2023 / The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna's mRNA platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health. The work undertaken as part of this partnership could expand the infectious disease targets for mRNA vaccine technology and strengthen pandemic preparedness and public health efforts in alignment with the 100 Days Mission, a global goal to compress vaccine development timelines to 100 days.

CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.

• Commitment builds on Regeneron’s longstanding efforts to develop the STEM talent pipeline as lead sponsor of the premier high school competitions, the Regeneron Science Talent Search (STS) and Regeneron International Science and Engineering Fair (ISEF)
• Regeneron will adapt successful initiatives it co-created in its local New York-based community to Nashville’s unique STEM ecosystem, helping to advance students to these premier competitions and inspire STEM careers
• Alongside this commitment, Regeneron is participating in Together for CHANGE, a national health and education equity initiative established by Nashville-based Meharry Medical College, further fueling the STEM talent pipeline

TARRYTOWN, N.Y., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology, engineering and mathematics (STEM) ecosystem through high-quality, equitable engagement programs for students and science teachers. Regeneron’s goal is to engage and inspire the next generation of scientific leaders and innovators to help address some of humanity’s most challenging existential threats.

Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars.

DURHAM, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2023 Society for Clinical Research Sites (SCRS) Eagle Award (CRO category). Parexel received the award at the annual Global Site Solutions Summit held Oct. 6-8 in Hollywood, Fla. The SCRS Eagle Award recognizes the sponsor and CRO committed to outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.

R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity.

OrganaBio launches decentralized support division for vaccine and cell and gene therapy clinical trials

New plant will supply cell therapy products for late-stage clinical trials and future product launches  / Supports clinical studies with BlueRock Therapeutics’ investigational cell therapy for Parkinson’s Disease bemdaneprocel (BRT-DA01) / New facility located in Berkeley, California, USA 

• Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRAS^G12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRAS^G12C Mutation and Who Have Received at Least One Prior Systemic Treatment
• KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRAS^G12C Mutation as well as in Other Indications
• Mirati’s Promising Pipeline Includes a Potent Selective PRMT5/MTA Inhibitor, MRTX1719, a Potential First-in-Class and Best-in-Class Asset; and Early Clinical Pipeline Features a KRAS and KRAS Enabling Program, including MRTX1133, and a SOS1 Inhibitor, MRTX0902

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.^® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, representing an additional $1.0 billion of value opportunity. The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.